One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
第一作者:
Mark C,Genovese
第一单位:
From Stanford University, Palo Alto, California, USA; Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium; Novartis Pharma AG, Basel, Switzerland; NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; Medical Plus, Uherske Hradiste, Czech Republic; Arthritis Clinic, Jackson, Tennessee, USA; Konkuk University Medical Center, Seoul, South Korea; Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; Centre for Inflammatory Joint Diseases, Munich, Germany; Kobe-Konan Yamate Clinic, Kobe, Japan; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
作者:
主题词
抗体, 单克隆(Antibodies, Monoclonal);抗风湿药(Antirheumatic Agents);关节炎, 类风湿(Arthritis, Rheumatoid);双盲法(Double-Blind Method);人类(Humans);注射, 皮下(Injections, Subcutaneous);治疗结果(Treatment Outcome)
DOI
10.3899/jrheum.130637
PMID
24429175
发布时间
2019-12-10
- 浏览100
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文